70 related articles for article (PubMed ID: 1878702)
1. Is graft versus leukaemia separable from graft versus host disease?
Jiang YZ; Macdonald D; Cullis JO; Barrett AJ
Bone Marrow Transplant; 1991; 7 Suppl 2():26. PubMed ID: 1878702
[No Abstract] [Full Text] [Related]
2. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
Champlin R; Giralt S; Przepiorka D; Ho W; Lee K; Gajewski J; Nimer S; Andersson B; Wallerstein R; Ippolito C
Prog Clin Biol Res; 1992; 377():385-94; discussion 395-8. PubMed ID: 1438435
[No Abstract] [Full Text] [Related]
3. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
Champlin R; Jansen J; Ho W; Gajewski J; Nimer S; Lee K; Territo M; Winston D; Tricot G; Reichert T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
[No Abstract] [Full Text] [Related]
4. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
5. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
Gaschet J; Mahé B; Milpied N; Devilder MC; Dréno B; Bignon JD; Davodeau F; Hallet MM; Bonneville M; Vié H
J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
[TBL] [Abstract][Full Text] [Related]
6. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
Porter D; Levine JE
Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
9. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
Friedman TM; Azhipa O; Zilberberg J; Tkachuk Y; Hsu JW; Rowley SD; Goldberg SL; Korngold R; Pecora AL; Preti RA
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1092-5. PubMed ID: 17084373
[No Abstract] [Full Text] [Related]
11. Allogeneic bone marrow transplantation: state of the art and future directions.
Goldman JM
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():133-4. PubMed ID: 2653489
[TBL] [Abstract][Full Text] [Related]
12. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Tabayashi T; Yamada K; Takeuchi M
Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
[TBL] [Abstract][Full Text] [Related]
13. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
Jiang YZ; Cullis JO; Kanfer EJ; Goldman JM; Barrett AJ
Bone Marrow Transplant; 1993 Feb; 11(2):133-8. PubMed ID: 8435662
[TBL] [Abstract][Full Text] [Related]
14. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
15. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
Westermann J; Lessen A; Schlimper C; Baskaynak G; le Coutre P; Dörken B; Pezzutto A
Br J Haematol; 2006 Jan; 132(1):32-5. PubMed ID: 16371017
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors.
Goldman JM; Mackinnon S
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():38-9. PubMed ID: 2627622
[TBL] [Abstract][Full Text] [Related]
18. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
19. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.
Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL
J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886
[TBL] [Abstract][Full Text] [Related]
20. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
